Latest Production Development News

Complii FinTech Solutions reported modest ARR growth and a key institutional contract in Q4 FY26, while advancing product development and managing cash flow pressures.

Genetic Signatures has completed a major restructure delivering $5 million in annual savings from FY2027 and secured a decade-long supply contract with Denmark’s Hvidovre Hospital, while posting $14.8 million revenue for FY2026 amid market pressures.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Green360 Technologies has locked in its inaugural commercial supply contract with Holcim Australia for up to 4,800 tonnes of its MKX-CC low-carbon cement replacement, marking its shift from development to commercial sales amid tightening supplementary cementitious material supplies.

Locate Technologies’ Q4 FY26 update highlights a 54% surge in Locate2u revenue to NZ$1.20 million, driving normalised EBITDA into positive territory. AI integration accelerated product development and customer onboarding, while capital moves included a share buyback and royalty conversion.

Wrkr Ltd has completed a $10 million placement and launched a $2 million Share Purchase Plan to fund accelerated employer onboarding and platform enhancements ahead of Payday Super’s phased rollout.

Codeifai Limited has secured $770,000 through a share placement, aiming to expand its AI capabilities into self-service SaaS and geospatial intelligence sectors.

Elsight Limited (ASX:ELS) has shattered its revenue records in H1 2026, delivering a nearly fourfold increase over the prior year alongside expanding US defence contracts and new product launches.

Praemium’s total Funds Under Administration surged 21% to $77.9 billion in FY26, driven by strong platform net inflows and robust growth in non-custodial portfolio administration.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

QuickFee Limited’s FY26 results show stable normalised revenue with Australian loan originations surging 40%, offsetting US finance declines. The company ups its Australian debt facility and confirms EBITDA guidance, eyeing growth in both markets.